The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference?
- 946 Downloads
About sixty percent of the US population of those age fifty and older are currently up to date with colorectal cancer screening recommendations. Has this level of screening made a difference for reducing colorectal cancer (CRC) incidence and/or mortality? Randomized controlled trials of guaiac-based fecal occult blood tests, which have relatively low sensitivity but high specificity for CRC, have shown a modest effect but with a long-term reduction in CRC mortality. Newer fecal immunochemical tests are expected to have a greater effect. Randomized controlled trials of flexible sigmoidoscopy have also demonstrated a reduction in CRC mortality. Observational studies of screening colonoscopy suggest an effect of greater than fifty percent reduction in CRC mortality. We have assessed past trends of colorectal cancer screening in the US population which suggest that more than fifty percent of the decline in colorectal cancer mortality can be attributed to the increased acceptance and uptake in colorectal cancer screening. Current and future levels of increased screening could provide for even larger reductions for the USA. Colorectal cancer screening has and will continue to make a significant impact on reducing colorectal cancer mortality.
KeywordsColorectal cancer screening Impact of screening Incidence and mortality
This work is supported in part from the following grants: U01 CA-152959, U01 CA-151736, U54 CA-163262, R01 CA-079572, and P30 CA008748.
Conflict of interest
- 1.Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2011, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
- 18.Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595.CrossRefPubMedGoogle Scholar
- 24.Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer (Oxford, England). 1990;2013:3049–3054.Google Scholar
- 29.Bertario L, Russo A, Crosignani P, et al. Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case-control study. Eur J Cancer (Oxford, England). 1990;1999:973–977.Google Scholar
- 32.Nakama H. A study on the efficacy of a screening program for colorectal cancer in a small Japanese village. Clin Invest. 1994;72:117–121.Google Scholar
- 41.Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol. 2009;7:770–775; quiz 711.Google Scholar
- 50.Zauber AG, Winawer SJ. High-quality colonoscopies must be an integral part of screening and surveillance programs. Gastroenterology. 2006;130:620–621; author reply 621–622.Google Scholar
- 53.Singh H, Nugent Z, Mahmud SM, Demers AA, Bernstein CN. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol. 2010;105:663–673; quiz 674.Google Scholar